Showing results (11-20 of 46) with videos related to
Sort By:
Pageof 5
The Journal of Pharmacology and Experimental Therapeutics|October 19, 2013
A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxideYohannes T Ghebremariam, Daniel A Erlanson, John P CookeAnnual Review of Biophysics and Biomolecular Structure|May 14, 2004
Tethering: fragment-based drug discoveryDaniel A Erlanson, James A Wells, Andrew C BraistedRSC Medicinal Chemistry|December 23, 2022
Introduction to the themed collection on fragment-based drug discoveryDavid C Rees, Anna K H Hirsch, Daniel A ErlansonJournal of Biomolecular Screening|March 31, 2012
Development of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high-throughput chemical screeningYohannes T Ghebremariam, Daniel A Erlanson, Keisuke Yamada, et al.Journal of Medicinal Chemistry|October 15, 2016
Fragment-to-Lead Medicinal Chemistry Publications in 2015Christopher N Johnson, Daniel A Erlanson, Christopher W Murray, et al.Nature Reviews. Drug Discovery|July 16, 2016
Twenty years on: the impact of fragments on drug discoveryDaniel A Erlanson, Stephen W Fesik, Roderick E Hubbard, et al.Journal of Medicinal Chemistry|November 1, 2017
Fragment-to-Lead Medicinal Chemistry Publications in 2016Christopher N Johnson, Daniel A Erlanson, Wolfgang Jahnke, et al.Journal of Medicinal Chemistry|December 20, 2021
Fragment-to-Lead Medicinal Chemistry Publications in 2020Iwan J P de Esch, Daniel A Erlanson, Wolfgang Jahnke, et al.Biochemistry|May 25, 2005
Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residueStig K Hansen, Mark T Cancilla, Timothy P Shiau, et al.Pageof 5